" class="no-js "lang="en-US"> Koa Health Bolsters UK Leadership Team Appointing First UK Commercial Director as Business Grows - Medtech Alert
Sunday, March 03, 2024

Koa Health Bolsters UK Leadership Team Appointing First UK Commercial Director as Business Grows

Koa Health, a digital mental healthcare provider offering personalized mental health solutions backed by science, today announces that Charlotte Hilton has joined the company’s growing team as UK Commercial Director. Hilton will oversee all commercial efforts in the UK from sales and marketing to client success and partnerships. The news follows the appointment of Jennifer Gendron as U.S. Chief Commercial Officer and the unveiling of Koa Health’s heavyweight Scientific Advisory Board chaired by Tom Insel.

Dr Oliver Harrison, CEO, Koa Health said “Over the course of the pandemic there has been a sharp increase in the number of people experiencing mental health challenges across the UK, with government data showing twice as many people reporting symptoms of clinical depression and anxiety. We are delighted to welcome Charlotte, who brings fantastic experience of growing a digital mental health business. She will be pivotal in helping us realize our mission of providing effective and clinically-validated digital mental health solutions to users across the UK.”

Charlotte Hilton brings a wealth of experience in digital mental health and wellbeing. She most recently served as Healthcare and B2B Partnerships Manager at Headspace, where she led the development and management of the international team’s Enterprise partner channel strategy, specifically focused on UK health and benefits brokers and health insurance carriers. In addition to her expertise in business development and growth, Hilton has worked on end-to-end customer experience, supporting users directly on their mental wellbeing journey.

“Never before has there been such a need to scale access to tools and evidence-based care for mental health. Whilst the Government’s recent budget investment in NHS mental health facilities is a step in the right direction, the last 18 months have drastically exacerbated the need for mental health support across all demographics,” said Charlotte Hilton, UK Commercial Director, Koa Health.

“I was really impressed by what Koa Health is building – its approach of creating a comprehensive and accessible set of solutions addressing the full spectrum of mental healthcare, means the company is truly positioned to address this need for mental health support.  I couldn’t be more thrilled to leverage both my passion and years of experience in this sector to join a company so dedicated to making an impact of this significance.”

Koa Health, spun out of Telefonica’s moonshot factory last year with an oversubscribed Series A round totalling €30 million in funding, after five years of research and clinical trials to secure robust data and build out an industry-leading product roadmap. The company has a goal to provide access to a range of clinically validated, digital mental health solutions to help people flourish in a challenging and changing world.

The company’s debut product, Koa Foundations, was ranked No.1 by ORCHA for mental health and wellbeing applications. It is available to a combined employee population of over three million from dozens of companies, across 15 countries, including O2, Doctor Care Anywhere, Mapfre, and Education First. Koa Health is also closely collaborating with organizations including the UCL-Max Planck Centre, the London School of Economics and King’s College London, to build tech-driven mental healthcare products backed by clinical research.

Earlier this year Koa Health also launched its Wellbeing at Work report, which exposed the impact of COVID-19 on mental health in businesses across the US and UK, and organizations’ response to the crisis. For more information on Koa Health, please visit www.koahealth.com 

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more